Trevi Therapeutics Prices $150.8M Public Offering at Discount to Fund Clinical Trials

summarizeSummary

Trevi Therapeutics finalized its public offering, selling 11.6 million shares at $13.00 each, raising approximately $141.1 million in net proceeds to fund its Haduvio clinical development programs and extend its cash runway through 2029.

check_boxKey Events

• Public Offering Priced

  Trevi Therapeutics priced its underwritten public offering of 11.6 million shares of common stock at $13.00 per share, following the proposed offering on April 16, 2026.

• Significant Capital Raise

  The offering is expected to generate approximately $141.1 million in net proceeds, potentially increasing to $163.0 million if the underwriters' over-allotment option for an additional 1.74 million shares is fully exercised.

• Funding Clinical Development

  Proceeds will primarily fund the clinical development of Haduvio for chronic cough in IPF, non-IPF ILD, and RCC, as well as for working capital and other general corporate purposes.

• Extended Cash Runway

  The capital raise is projected to extend the company's cash, cash equivalents, and marketable securities to fund operations through 2029, including two planned Phase 3 trials for Haduvio in IPF.

auto_awesomeAnalysis

This 424B5 filing finalizes the terms and pricing of the public offering previously proposed on April 16, 2026. The company is raising a substantial amount of capital, approximately $141.1 million (or up to $163.0 million if the underwriters' option is fully exercised), which represents a significant percentage of its current market capitalization. The offering is priced at $13.00 per share, a discount to the last reported sale price of $14.54 on April 16, 2026, and today's stock price of $15.23. While the offering is dilutive to existing shareholders (approximately 9.04% to 10.39% share dilution), the proceeds are critical for funding the ongoing and planned Phase 2b and Phase 3 clinical trials for Haduvio across multiple indications (IPF, non-IPF ILD, and RCC). This capital infusion is expected to extend the company's cash runway through 2029, providing essential financial stability for its key drug development programs. Investors should weigh the immediate dilution and discount pricing against the extended operational runway and continued progress in clinical development.